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Abstract
Pathways producing and converting adenosine have hardly been investigated in human heart, contrasting work in other species. We
compared the kinetics of enzymes associated with purine degradation and salvage in human and rat heart cytoplasm assaying for
adenosine deaminase, nucleoside phosphorylase, xanthine oxidoreductase, AMP deaminase, AMP- and IMP-specific 5'-nucleotidases,
adenosine kinase and hypoxanthine guanine phosphoribosyltransferase (HGPRT). Xanthine oxidoreductase was not detectable in human
heart. The K m-values of the AMP-catabolizing enzymes were 2-5 times higher in human heart; the substrate affinity of the other
enzymes was in the same order of magnitude in both species. The maximal activity (VmaJ of adenosine kinase was the same in both
species, but HGPRT in man was only 12% of that in the rat. For human heart the Vmax-values of adenosine deaminase, nucleoside
phosphorylase, AMP- and IMP-specific 5'-nucleotidases, and AMP deaminase were 25-50% of those for rat heart. We conclude that
human heart is less geared to purine catabolism than rat heart as is evident from the lower activities of the catabolic enzymes.
Maintenance of the nucleotide pool may thus playa more important role in human heart.
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1. Introduction
Adenosine plays an important role in several cardio-
vascular processes. It is a potent vasodilator with depres-
sant effects on contractility, heart rate and conductance of
the pacemaker nodes [I]. The nucleoside may protect the
heart by 'preconditioning' through AI-receptor activation
[2]. The pathways that produce and catabolize adenosine in
hearts of several nonprimates have extensively been stud-
ied. In contrast, the activity and regulation of enzymes
involved in purine-nucleotide metabolism, like AK, ADA,
Abbreviations: ADA: adenosine deaminase; AK: adenosine kinase;
AMP-D: AMP deaminase; AOPCP: adenosine(a,/3-methylene)diphos-
phate; DTT: dithiothreitol; EHNA: erythro-9-(2-hydroxy-3-nonyI)adenine;
HGPRT: hypoxanthine guanine phosphoribosyltransferase; NP: nucleo-
side phosphorylase; NSC 113939: 4-amino-5-iodo-7-( /3-D-
ribofuranosyl)7H-pyrrolo[2,3-d]pyrimidine; 5'-NT: 5'-nucleotidase; PRPP:
phosphoribosylpyrophosphate; SAH: S-adenosylhomocysteine; XOD:
xanthine oxidoreductase
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NP, AMP-D and HGPRT, have been investigated to a
lesser extent in human tissues (see footnote for abbrevia-
tions). Also the presence of two isozymes of 5'-NT differ-
ing in substrate preferences (AMP- and IMP-specific) found
in various animal hearts [3] has not been confirmed in
human heart. Fig. I shows the pathways involved. Deacti-
vation of adenosine is possible through rapid breakdown
by ADA. This happens both inside and outside the cell [4];
the cellular process has been studied more thoroughly and
is likely to be more important. ADA activity varies consid-
erably in hearts of different species [5]. Metabolic in-
hibitors for purine degradation, such as allopurinol and
EHNA, are in use in cardioplegic solutions [6-8]' as are
adenosine catabolites like inosine to treat heart failure
[9, 10]. Those clinical trials assume the presence and activ-
ity of certain enzymes in the human heart. However, the
enzymological background for such studies is absent.
The purpose of this study was to investigate the kinetics
of cytosolic purine-metabolizing enzymes in human heart,
with emphasis on the regulation of the adenosine level.
This could give therapy and diagnostics with adenosine a
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2. Materials and methods
2.1. Human and rat myocardial homogenates
better fundamental basis. We compared the human-heart
data with those from rat heart, which is well described as a
metabolic system.
XOD 1
urate ~ xanthine
Fig. 1. Pathways of purine metabolism in rat and human heart. The
conversions of hypoxanthine to xanthine and to urate catalyzed by XOD
are probably absent in human heart. ADA, adenosine deaminase; AK,
adenosine kinase; AMP-D, AMP deaminase; HGPRT, hypoxanthine gua-
nine phosphoribosyltransferase; NP, nucleoside phosphorylase; 5'-NT,
5'-nucleotidase; SAHH, S-adenosylhomocysteine hydrolase; XOD, xan-
thine oxidoreductase. Assays were carried out at 30° C. The half-saturation
constant (K
rn
) and the maximal activity (Vrna) were deter-
mined, using Lineweaver-Burk linearization of the
Michaelis-Menten equation [12]. One unit is 1 ]Lmol sub-
strate converted in one min or 1 ]Lmol product formed in
one min at 30° C. Values are presented as the mean ± S.E.
The activity of AK was measured with the radiometric
method described by De long et al. [13]. There was no
difference in results obtained with fresh and frozen (for
::;; 2 days) supernatant fluids. The incubation mixture con-
tained 40 mM potassium phosphate (pH 7.0), 1.0 mM
GTP-lithium salt, 1.0 mM MgCI 2 , bovine serum albumin
0.05 mgjml, and [U-14C]adenosine (0.2-10 ]LM). After
10 min incubations were stopped by distribution of aliquots
from the reaction mixture on squares of DEAE-cellulose
(Whatman DE8}) to bind the reaction product, [14_C]AMP.
The squares were washed with 1 mM ammonium formate,
water and ethanol.
ADA activity was determined spectrophotometrically
(Hitachi U-2000 double-beam) at 265 nm according to
Coddington [14]. During 5 min incubations the conversion
of adenosine to inosine was measured in 50 mM potassium
phosphate buffer (pH 7.4) with substrate concentrations
between 2 and 100 ]LM.
The NP activity was analyzed spectrophotometrically
(Hitachi U-2000 double-beam) at 293 nm during 5 min
based on the method of Coddington [15] with modifica-
tions. Present were 0.1 M Tris (pH 7.4), xanthine oxidase
0.1 Ujml, and either various concentrations of KH 2 P04
(0.1-50 mM) with 0.3 mM inosine, or various concentra-
tions of inosine (0.02-1.0 mM) with 0.1 M K+-phosphate
buffer (pH 7.4).
The incubation mixture for the HGPRT determination
contained 0.4 mM hypoxanthine, 0.5 M TrisjO.05 M
MgCl 2 (pH7.4), 8 mM PRPP and 10% Triton X-100 in the
ratio 10: 10: 10: 1. The reaction was started by adding 10
]Ll supernatant fluid to 50 ]Ll incubation mixture. After
120 min at 30° C the reaction was stopped with HCI04 (0.4
M final concentration). Samples were kept on ice for 10
2.3. Determination of enzyme kinetics
2.2. Inhibitors
The AK inhibitor NSC 113939 was a gift of the Na-
tional Cancer Institute (Bethesda, MD, USA). 5-Iodotu-
bercidin (4-amino-5-iodo-7-( /3-D-ribofuranosyI)pyrrolo
[2,3-d]pyrimidine), another AK inhibitor, was obtained
from Research Biochemicals (Natick, MA, USA). The
ADA inhibitor pentostatin (2'-deoxycoformycin, i.e., R-3-
(2-deoxy-/3-D-erythro-pentofuranosyI)-3,6,7,8-tetrahydro[4,
5-d][I,3]diazapin-8-oI) was from Parke-Davis (Detroit, MI,
USA). EHNA, an alternative ADA inhibitor, was a gift
from Wellcome Research Laboratories (Beckenham, Kent,
UK). AOPCP, a potent membrane 5'-NT inhibitor, was
bought from Sigma (St. Louis, MO, USA).
HGPRT
hypoxanthine
AMP-D
AMP ~ IMP
AK i lSI-NT lSI-NT
SAH~ adenosine~ inosine
SAHH ADA
Human hearts were obtained from transplantation pa-
tients with end-stage heart failure (cardiomyopathy, hyper-
trophy, atherosclerosis, myocarditis etc.) of the Thoraxcen-
ter, Erasmus University Rotterdam. The hearts were ar-
rested with cold St. Thomas' Hospital cardioplegic solu-
tion, excised and cooled on ice; they arrived in the labora-
tory within 10 min. Nonfibrotic samples from the left-
ventricular wall were cut into pieces. Some control experi-
ments (n = 4) were done on healthy donor hearts, unused
for transplantation for clinical reasons. Because the kinetic
data obtained were comparable to the ones from explanted
diseased hearts, the data were pooled. Hearts were also
obtained from anesthetized male adult Wistar rats (250-270
g) as described before [II]. For the AMP-D assay, 10%
(wjv) homogenates were made in 20 mM Na+-dimethyl-
glutarate (pH 7.4), 1 mM EDTA and 0.1 mM DTT. For
HGPRT 20% (wjv) homogenates were made in 0.5 M
Tris and 0.05 M MgCl 2 (pH 7.4). The other assays were
carried out in 5% (wjv) homogenates prepared as previ-
ously described [11]. The 5 and 10% homogenates were
centrifuged (Sigma 2K15, Braun, Melsungen, Germany)
for 5 min, at 12000 X g and 4° C, whereas the 20%
homogenate was centrifuged for 10 min, at 600 X g and
4° C. To get rid of small molecules, PD-I0 Sephadex
columns (G-25M) were loaded with supernatant fluids and
washed with buffer. Extracts were immediately used in the
assays or stored at - 80° C.
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min and centrifuged for 4 min, IS 000 X gat 4° C. K 2 HP04
was added to 50 fLl supernatant fluid in a final concentra-
tion of 0.14 M. The samples were analyzed on HPLC as
described previously [16].
For AMP-D determination Moss' method [17] modified
by Meghji et al. [5] was used. The reaction mixture
contained 20 mM sodium dimethylglutarate (pH 7.0), I
mM EDTA, 0.1 mM dithiothreitol, 0.15 M KCI, I fLM
EHNA, I mM ATP, and AMP in the range 0.5-15 mM.
The reaction was stopped with 50% HCI04 after 20 min.
After centrifugation for 5 min at 4° C, IS 000 X g, super-
natant fluids were taken and neutralized with 1.2 M
K 2C03/30 mM EDTA. After centrifugation the super-
natant fluid was taken to estimate ammonia spectrophoto-
metrically at 625 nm according to Chaney and Marbach
[ 18].
5'-NT was determined at 37° C as described by
Skladanowski et al. [19]. The assay is based on the method
of Newby [20] with some modifications for 5'-nucleoti-
dases of different specificity [2 I]. For both assays the
conditions adopted secured lack of cross reactivity of the
two forms. Briefly, the final concentrations in the incuba-
tion mixture for the AMP-specific form of 5'-NT were:
100 mM TES (or Hepes)/NaOH, pH 7.0, 10 mM MgCI 2 ,
30 mM NaCI, I mM ADP and AMP between 0.5-20 mM.
To prevent conversion of adenosine to AMP and/or ino-
sine, 2 fLM 5-iodotubercidin and 10 fLM EHNA were
included. The reaction was stopped with 50 fLl 1.3 M
HCI04 after 1.5 to 3 min. Samples were kept on ice for 30
min, deproteinized, centrifuged and analyzed with HPLC
[22]. The incubation conditions for the IMP-specific form
of 5'-NT were: 100 mM imidazole/HCI, pH 6.5, 50 mM
MgCI 2 , 500 mM NaCI, 2.5 mM IMP and 2.5 mM ATP.
The time course was linear for both assays. We recalcu-
lated the results from the earlier study [19] for 30° C, using
factors of 0.75 for human and 0.71 for rat AMP- and
IMP-preferred 5'-NT, which we determined experimen-
tally.
3. Results and discussion
3.1. Adenosine kinase
Use of the AK inhibitors NSC 113939 (50 fLM) and
5-iodotubercidin (5 fLM), proved that our AK measure-
ments were specific; they inhibited the reaction almost
completely (94% and 96%, respectively). Inclusion of the
ADA inhibitor pentostatin (I fLM) in the reaction mixture
did not change the Vmax ' which shows that ADA did not
interfere with the assay. Addition of AOPCP (50 fLM), a
potent membrane 5'-NT inhibitor [23], had no influence on
the AK activity. We avoided thus possible product conver-
sion by ecto-5'-NT in the assay. The Vmax of AK in human
myocardial homogenates was the same as in rat heart
(Table I). In both species, the Km-values were in the low
micromolar range (Table I). The observed species-dif-
ferences are in line with those suggested earlier [25].
3.2. Adenosine deaminase
The inhibitor pentostatin (3 fLM) completely abolished
ADA activity, showing that other reactions did not inter-
fere with our assay. In human heart the Vmax was about
30% of that in rat heart (Table I); however, the Km-values
were almost identical (Table I). Our results on ADA
activity in human and rat heart agree with those published
by Meghji et al. [5], although they made only one-point
estimations. The kinetic data on rat heart are in line with
Arch and Newsholme [26].
Table I
Maximal activity (Vmax ) and half-saturation constants (K m ) of the adenylate-metabolizing enzymes (E) in rat and human hearts
Enzyme Substrate V.nax (mU/ g wet weight) K m (/-LM)
Rat Human Rat Human
AK adenosine 38.9 ± 3.2 (3) 37.7 ± 0.8 (9) 2.30 ± 0.20 (3) 2.06 ± 0.13 (9)
ADA adenosine 715 ± 36 (3) 212± l7(I1) 21.0 ± 0.5 (3) 20.3 ± 3.5 (I I)
NP inosine 738 ± 52 (3) 245 ± 25 (8) 60.7 ± 8.6 (3) 62.1 ± 4.8 (8)
P; 441 ± 26 (6) 134±12(5) 1540 ± 100 (6) 2070 ± 570 (5)
XOD xanthine 38.6 ± 1.8 (5) a <I 4.5 ± 0.4 (5) a n.d.
hypoxanthine 38.1 ± 4.3 (5) a <I 3.0 ± 0.3 (5) a n.d.
HGPRT hypoxanthine 299 ± 44 (5) 36.0 ± 2.6 (5) N.D. N.D.
AMP-D AMP 1837 ± 152 (3) 976 ± 20 (5) 1120 ± 130 (3) 2780 ± 180 (5)
5'-NT AMP 362 ± 17 (3) 128 ± 37 (6) 1220 ± 70 (3) 5320 ± 570 (6)
IMP 533 ± II (5) 35 ± 9 (6) 20 ± 30 (5) 510±70(6)
Enzyme assays were done on myocardial supernatant fluids. The activity of the catabolizing enzymes proved to be in human heart 12-50% of that in rat
heart; the activity of adenosine kinase was the same in both species. In human heart the K m-values were in the same order of magnitude as in rat heart,
although they were at least twice higher for mononucleotide-catabolizing enzymes. Mean ± S.E. with number of experiments in parentheses. For
abbreviations, see legend to Fig. I. n.d., not detectable. N.D., not determined.
a Data from [24].
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3.3. Nucleoside phosphorylase a hyperbolic one. Our findings partly confirm other litera-
ture data on rat [32,33] and human heart [34].
In human myocardial tissue, the Vmax of NP with ino-
sine or KH 2 P04 as variable substrate was about 30% of
that in rat (Table 1). The Vmax estimated with varying
inosine concentrations was about twice higher than with
KH 2 P04 as variable substrate. This could be attributed to
inhibition by the Tris-buffer used when phosphate was
varied. The K m' however, was similar in both species
(Table 1). We are unaware of kinetic data on human NP
activity except for a qualitative estimation of activity in
human and rat heart [27].
3.4. Xanthine oxidoreductase
Earlier our group could not detect XOD actIvIty in
human-heart homogenate. We found a very low activity in
perfused diseased human hearts [28], agreeing with the
results of others [see, e.g., [29,30]]. In rat heart we deter-
mined activity [31] and kinetic data for XOD with hypox-
anthine and xanthine as substrate [24]. For both substrates
the Vmax-values were the same; the Km-values were in the
lower micromolar range (Table 1).
3.5. Hypoxanthine guanine phosphoribosyltransferase
In human heart the Vmax of HGPRT with hypoxanthine
as substrate was only 12% of the value for rat heart. Purine
degradation, but also purine salvage to IMP via HGPRT,
appears slow in human heart compared with rat heart.
3.6. AMP deaminase
Side reactions only interfered in rat heart at substrate
concentrations higher than 15 mM by an artifactual sharp
increase of ammonia production. The dependence of am-
monia production on AMP concentration was biphasic in
rat- but not in human-heart homogenate. HPLC analysis of
the postreactional mixtures revealed that the accelerated
ammonia production at ~ 15 mM AMP correlated with
formation of adenosine and inosine. Then the EHNA con-
centration (I fLM) seemed too low to inhibit ADA com-
pletely. At low concentrations of AMP, the production of
adenosine, if detectable, was not accompanied by in-
creased inosine, showing effective inhibition of ADA. We
decided to estimate activity values at substrate concentra-
tions ~ 10 mM. Then we observed a Vmax for rat heart
AMP-D twice higher than for human heart, where the
delayed increase of ammonia did not take place (Table 1).
The Km-values for AMP-D were similar in human and rat
heart, i.e., in the lower millimolar range (Table 1). We
found lower activities of AMP-D in both species than
Meghji et al. [5]. This is presumably due to their overesti-
mation caused by EHNA's incomplete inhibition of ADA
at 25 mM AMP. The presence of 1 mM ATP in the
AMP-D assay ensured that the sigmoidal curve turned into
3.7. 5'-Nucleotidase
In human heart the Vmax of AMP- and IMP-preferred
5'-NT was 25-30% of that in rat heart (Table 1). The
Km-values for both substrates were 2-4 times higher in
human heart (Table 1), suggesting a lower affinity of
5'-NT for AMP and IMP in man. Our results in rat heart
were comparable with those from Truong et al. [35]. We
found a 13-fold lower initial concentration of inosine
accumulated in freshly prepared human-heart supernatant
fluids compared to rat-heart ones. Concentrations were
8.6 ± 1.2 fLM (n = 7) and 116 ± 3 fLM (n = 7), respec-
tively. Additive effects of lower AMP dephosphorylation
by 5'-NT and adenosine deamination by ADA in the
human heart caused this difference with rat heart.
3.8. Physiological implications
One has to be cautious in the interpretation of the Vmax
of a particular reaction. We realize that we calculated
kinetic values on enzymes present in cytosol, not on
purified proteins. On the other hand, we avoided the
instability problems sometimes seen with purified en-
zymes. In human myocardium the maximum velocities of
the enzymes catabolizing adenylate to hypoxanthine
(AMP-D, AMP- and IMP-specific 5'-NT, ADA and NP)
were in a highly regular order 25-50% of those in rat
heart. The Vmax of the anabolic enzyme AK was the same
in both species, whereas the maximal HGPRT activity for
human heart was only 12% of that observed for rat. We
found the Km-values of AK, ADA and NP to be either the
same or in the same order of magnitude for both species.
Thus we expect that the affinity of these enzymes to their
substrates is similar. The Km-values of AMP-D and 5'-NT
(AMPlIMP) were higher in human than in rat heart,
suggesting a lower affinity of these two enzymes in human
heart. Slower purine breakdown but not purine salvage via
AK possibly protects the human heart at an earlier stage
through purine accumulation instead of rapid breakdown to
urate. Maintenance of the cardiac nucleotide pool may play
a more important role in man than in rat.
A possible difference in tissue adenosine levels between
human and rat heart may be assessed by relating the flux
rate determined from AMP to adenosine with the rate of
adenosine degradation to inosine. From the data (Table I)
it appears that the lower Vmax-value for Sf-nucleotidase in
human heart is compensated by slower adenosine
catabolism.
Borst et al. [36] determined kinetic values for SAH
hydrolase in patients with hypertrophic obstructive car-
diomyopathy. Its activity is very low compared to the other
enzyme activities involved in purine metabolism in human
heart. We reported earlier that SAH hydrolase activity does
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not contribute significantly to adenosine during ischemia,
but could playa role during normoxia [37].
Our results give the maximal velocity obtainable and
affinity toward substrates for the enzymes investigated.
Free cytosolic AMP-concentrations in cardiomyocytes are
probably in the submicromolar range even under ischemic
conditions [38]. This is far below the Krn of 5'-NT and
AMP-D. We suggest that the rise in AMP-concentration
due to hypoxia will give a large response in adenosine
formation, reinforced by allosteric activation of 5'-NT. The
next step is the rapid conversion to inosine by ADA (see
Table O.
The breakdown of inosine to hypoxanthine by NP de-
pends on the concentration of phosphate. Its physiological
concentration in rat heart exceeds the K rn (phosphate) for
NP by a factor of 1.5 [39]. When the free phosphate
concentration rises (about three times) due to ischemia, the
activity of NP might increase, approaching the Vrnax-value.
Thus, the intracellular phosphate concentration is possibly
rate-limiting for adenosine degradation to hypoxanthine.
We confirmed this in our AMP-specific 5'-NT assay: the
amount of inosine present in the supernatant fluid - stoi-
chiometric with phosphate liberated from AMP - was
converted to hypoxanthine by NP both in rat and human
heart. Hypoxanthine salvage to IMP by HGPRT in human
heart is possible but slow.
3.9. Cardiac IMP production
In skeletal muscle and liver, IMP produces inosine.
There is consensus that in ischemic heart muscle like in
brain, AMP degradation via adenosine is preferred. Olsson
and Pearson suggested that the IMP pathway is dominant
in cells generating ATP predominantly through anaerobic
glycolysis; the adenosine pathway seems prominent in
organs relying on oxidative phosphorylation [40]. Our in
vitro data would show that the capacity of the IMP path-
way exceeds the adenosine pathway in both species (see
Table O.
Association with membrane phospholipids activates
AMP-D [41]. Recently, Tanfani et al. suggested that syn-
chronized AMP-D inhibition by ATP decrease and this
association loss in ischemic heart shifts adenylate to
adenosine production by 5'-NT [41]. The cardioplegia-arre-
sted human heart produces considerable amounts of adeno-
sine besides inosine [42,43]. However, IMP accumulates in
human heart as well [43].
3. 10. Limitations of the study
We measured the kinetics of the enzymes in ho-
mogenates, which consist of endothelial cells (ca. 4%) and
cardiomyocytes. The localization of the enzymes in my-
ocytes and/or endothelial cells differs in species. For
example, nucleoside phosphorylase in guinea-pig heart is
completely localized in the endothelial cells [44]; in rat
heart we found this enzyme to be also present in the
myocytes [11]. It is not known if the distribution of the
enzymes discussed in this paper is the same in rat and
human heart. We also did not deal with kinetics of nucleo-
side transport in cardiomyocytes and endothelial cells in
this study. We only measured the kinetics of the enzymes
involved in purine metabolism under optimal conditions in
human and rat heart.
3.1 I. Conclusion
Human heart with its slower rate of adenosine forma-
tion from AMP, its lower activity of purine-catabolizing
enzymes and its virtual absence of XOD, is less geared to
adenosine production and subsequent degradation than rat
heart.
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